Developer docs
API playgroundTry for free, no card

Search company profiles

Synairgen

Full company profile

uuid0005zdm

Namestring
Synairgen
Legal namestring
Synairgen plc (UK operating entity); Synairgen Research Ltd (research subsidiary)
Websiteurl
synairgen.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Synairgen plc is a UK-based clinical-stage respiratory biotechnology company whose sole asset is SNG001, an investigational inhaled formulation of interferon beta (IFN-β) being developed as a host-directed, broad-spectrum antiviral delivered directly into the lungs for severe viral lung infections. The technology is designed to restore IFN-β levels suppressed by viral pathogens and applies across multiple viruses including SARS-CoV-2, influenza, RSV, adenovirus, parainfluenza and rhinovirus, with delivery via a custom vibrating mesh nebuliser developed in partnership with Aerogen for use in mechanically-ventilated ICU patients. SNG001 has been evaluated across multiple Phase 1-3 programmes spanning asthma (SG004, SG005), COPD (SG015), hospitalised COVID-19 (SG016 Phase 2 in The Lancet Respiratory Medicine, SG018 SPRINTER Phase 3 in 17 countries), the NIH/NIAID-sponsored ACTIV-2 platform trial, the observational UNIVERSAL study with the University of Southampton and Janssen, and most recently the global Phase 2 INVENT study targeting 550 mechanically-ventilated patients with 28-day all-cause mortality as the primary endpoint.

The business model has historically been pre-revenue biotech development: funding has come from equity (notably a £18 million subscription from majority shareholder TFG Asset Management in January 2025) rather than product sales, and the intended future commercialisation pathway was a drug-device combination product (SNG001 + Aerogen nebuliser) sold to hospital systems, ICU networks and hospital pharmacies on a per-treatment pricing basis. Following the February 2026 termination of the INVENT trial due to under-recruitment and withdrawal of further financing from Tetragon Partners on behalf of TFG-managed funds, Synairgen is winding down operations and pursuing a Members Voluntary Liquidation in H2 2026, while conducting outreach to over 100 pharmaceutical and biotech companies to identify any potential acquirer for SNG001 intellectual property. The company has completed an all-staff redundancy, is closing its Southampton laboratory facility and US/EU subsidiaries, and was re-registered as a private limited company after AIM cancellation in April 2025.

Short descriptiontext

Synairgen is a UK clinical-stage respiratory biotech developing SNG001, an inhaled interferon beta broad-spectrum antiviral for severe viral lung infections, delivered to mechanically-ventilated ICU patients via a custom Aerogen nebuliser. The company is winding down and pursuing Members Voluntary Liquidation in H2 2026.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouthampton, United Kingdom
HQ citystring
Southampton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory biotechnology, inhaled antivirals, interferon beta therapy, drug-device combination, clinical-stage biopharmaceutical
Industry4 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inhaled Antiviral Biologics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1No active revenue streams (winding down)
TypeLicensing Royalties
Description

Clinical-stage biotech with no approved or commercial products; company is winding down operations and pursuing Members Voluntary Liquidation in H2 2026. SNG001 has never been approved or available commercially. Intended future commercialisation via out-licensing or sale of SNG001 asset.

synairgen.com
2Asset divestiture / IP licensing (exploratory)
TypeLicensing Royalties
Description

Company plans to explore whether there is any opportunity to divest certain intellectual property assets related to SNG001, with outreach to over 100 pharmaceutical and biotech companies to identify potential acquirers for the sole asset.

synairgen.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
Pricing details1 tier
1No product pricing available; investigational therapy not approved or commercially available anywhere.
ModelOtherBilling cadencePay-as-you-go
Notes

SNG001 is still being investigated and is not approved for use anywhere in the world and is therefore not available for patients or clinicians commercially.

synairgen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1SNG001
Description

Investigational inhaled formulation of interferon beta (IFN-β) developed by Synairgen as a broad-spectrum antiviral for severe viral lung infections.

synairgen.com
+1 more record
Core offering1 text field

Synairgen is a clinical-stage respiratory biotechnology company developing SNG001, an investigational inhaled formulation of interferon beta (IFN-β) delivered directly to the lungs as a host-directed broad-spectrum antiviral for severe viral lung infections. The company's programmes span asthma, COPD, COVID-19 and mechanically-ventilated ICU patients, with delivery via a custom nebuliser co-developed with Aerogen Ltd. Following termination of the Phase 2 INVENT trial in February 2026, Synairgen is winding down operations and seeking asset acquirers for SNG001.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Approximately 2 million people hospitalised in the US annually due to severe respiratory viral infections (HCUP).
+4 more records
Product overview1 text field

Synairgen plc is a UK-based clinical-stage respiratory biotechnology company whose sole clinical-stage asset is SNG001, an investigational inhaled formulation of interferon beta (IFN-β) being developed as a host-directed, broad-spectrum antiviral delivered directly into the lungs for severe viral lung infections. SNG001 has been evaluated across a portfolio of named clinical programmes spanning multiple patient populations: SG004 (Phase 1 in moderate asthma) and SG005 (Phase 2 in moderate-to-severe asthma), SG015 (Phase 2 in COPD), SG016 (Phase 2 in hospitalised COVID-19), SG018 SPRINTER (Phase 3 in hospitalised COVID-19 across 17 countries), the NIH/NIAID-sponsored ACTIV-2 trial, the observational UNIVERSAL study in collaboration with the University of Southampton and Janssen, and most recently the global Phase 2 INVENT study in mechanically-ventilated ICU patients, which dosed its first patient on 8 December 2025 before being terminated in February 2026 due to insufficient enrolment. Following the INVENT termination and the withdrawal of further financing from Tetragon Partners/TFG Asset Management UK LLP, Synairgen is winding down operations and pursuing a Members Voluntary Liquidation in H2 2026, while conducting outreach to potential acquirers for SNG001, which is delivered using a custom aerosol device developed in partnership with Aerogen Ltd.

Product and service1 record
1SNG001 (inhaled interferon beta)
CategoryInvestigational inhaled antiviral biologic
Description

Investigational inhaled formulation of interferon beta (IFN-β), a naturally occurring broad-spectrum antiviral protein, designed to restore IFN-β levels in the lungs and boost antiviral responses in patients with severe viral lung infections (RSV, rhinovirus, influenza, SARS-CoV-2, MERS-CoV, etc.). Delivered via a nebuliser, including on invasive mechanical ventilation, through a custom device developed with Aerogen Ltd. Granted FDA Fast Track status; not approved anywhere in the world and is the sole asset of Synairgen.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Strategic partnership announced 12 November 2025 to develop and deliver a custom aerosol device for SNG001 (inhaled interferon-beta). Builds on a long-standing relationship and unites Aerogen's vibrating mesh nebuliser platform and manufacturing expertise with Synairgen's drug development programme. Manufacturing, supply and exclusivity terms are in place for future commercialisation. Aerogen's Solo nebuliser is the gold standard for respiratory patient care in over 80 countries, treating over 30 million patients worldwide.

Strategic tierImportantTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-08
Description

Asset Match, an FCA-authorised firm (FRN 579310), operates an electronic off-market dealing facility for Synairgen ordinary shares following the company's cancellation from AIM trading in April 2025. Shares were admitted to trading on Asset Match on 8 May 2025 ahead of the first auction. Facility to remain in place for a minimum of two years from AIM cancellation (until 9 April 2027). Periodic auctions enable existing shareholders and new investors to trade shares.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-09-05
Description

Long-standing research and academic collaboration. Synairgen was founded as a 2003 spin-out from the University of Southampton by three of its professors. Co-leads the UNIVERSAL observational trial. Prof Tom Wilkinson is a key opinion leader and Prof Ratko Djukanovic is a co-founder and Professor of Medicine.

4U.S. National Institute of Allergy and Infectious Diseases (NIAID) / NIH ACTIV-2 Programme
Strategic tierStrategic (Us Government-Sponsored)TypeStrategic or Co-development PartnerAnnounced on2021-10-01
Description

SNG001 was investigated independently as part of the US National Institute of Health's ACTIV programme to accelerate the development of the most promising COVID-19 treatments. The ACTIV-2 study (ClinicalTrials.gov Identifier: NCT04518410) was sponsored by NIAID. An Independent Data Safety Monitoring Board recommended advancement from Phase 2 to Phase 3 in October 2021, but NIAID halted all patient recruitment in March 2022.

synairgen.com
Strategic tierStandard AdviserTypeImplementation/ SI/ Consulting Partner
Description

Auditors of Synairgen. Based at Level 12, Thames Tower, Station Road, Reading, RG1 1LX, UK. Reports to the Audit Committee chaired by independent Non-Executive Director John Bradshaw.

6MUFG Corporate Markets
Strategic tierStandard AdviserTypeImplementation/ SI/ Consulting Partner
Description

Registrars for Synairgen, based at Central Square, 29 Wellington Street, Leeds, LS1 4DL. Issue share certificates on behalf of SNG to registered legal shareholders following AIM cancellation.

synairgen.com
7Fieldfisher
Strategic tierStandard AdviserTypeImplementation/ SI/ Consulting Partner
Description

Solicitors for Synairgen, based at Riverbank House, 2 Swan Lane, London, EC4R 3TT.

synairgen.com
Strategic tierStandard AdviserTypeGTM or Marketing Partner
Description

Financial PR and Investor Relations adviser, based at 85 Gresham Street, London, EC2V 7NQ. Handles media and investor relations for Synairgen including distribution of corporate updates and clinical trial announcements.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage developer of DAS181, an inhaled antiviral for severe respiratory infections including parainfluenza and influenza. Direct competitor to Synairgen's inhaled host-directed antiviral approach in the hospitalised/immunocompromised respiratory niche.

TypeBroad incumbent
Description

Japanese pharma with approved antivirals (baloxavir for influenza, Xocova/ensitrelvir for COVID-19). Competes with SNG001 in the respiratory antiviral space via direct-acting mechanisms with much larger commercial infrastructure.

TypeEmerging player
Description

Develops mRNA-based vaccines and therapeutics for infectious disease including respiratory viruses (e.g., Kostaive for COVID-19). Comparable clinical-stage respiratory biotech targeting viral lung infections through a different modality.

TypeDirect peer
Description

Clinical-stage biotech developing inhaled therapeutics for respiratory diseases using its iSPERSE/iCALM delivery platforms. Highly comparable as a small inhaled-respiratory biotech targeting severe pulmonary indications.

TypeEmerging player
Description

Clinical-stage developer of oral vaccines for respiratory viruses including RSV and influenza. Comparable small-cap respiratory infectious disease biotech with similar wind-down/trial-recruitment sensitivities.

TypeDirect peer
Description

Late-stage biopharmaceutical company developing RiVax (ricin toxin) and other infectious disease/vaccine assets. Comparable small clinical-stage biotech operating in the antiviral/anti-infective space with similar capital constraints.

TypeBroad incumbent
Description

Leading RNAi therapeutics company with programmes in infectious disease (incl. respiratory targets). Larger incumbent with broader modality portfolio and stronger balance sheet but overlapping antiviral development programmes.

TypeBroad incumbent
Description

Develops and commercialises Paxlovid (nirmatrelvir/ritonavir) for COVID-19 and other respiratory antivirals. The most likely strategic acquirer profile for SNG001 given its hospital antiviral portfolio and ICU commercial reach.

TypeEmerging player
Description

Clinical-stage respiratory biotech (acquired by GSK in 2024) developing inhaled therapeutics for severe asthma and COPD exacerbations. Closely comparable single-asset inhaled respiratory biotech whose acquisition illustrates the exit path Synairgen is pursuing.

10Translate Bio (Sanofi)
TypeBroad incumbent
Description

Sanofi-owned mRNA therapeutics platform that was developing vaccines for respiratory viruses including influenza. Represents the broader incumbent respiratory antiviral space and a potential acquirer/category competitor for SNG001.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synairgen

Inhaled Antiviral Biologicssynairgen.com

Synairgen is a UK clinical-stage respiratory biotech developing SNG001, an inhaled interferon beta broad-spectrum antiviral for severe viral lung infections, delivered to mechanically-ventilated ICU patients via a custom Aerogen nebuliser. The company is winding down and pursuing Members Voluntary Liquidation in H2 2026.

What Synairgen does

Synairgen plc is a UK-based clinical-stage respiratory biotechnology company whose sole asset is SNG001, an investigational inhaled formulation of interferon beta (IFN-β) being developed as a host-directed, broad-spectrum antiviral delivered directly into the lungs for severe viral lung infections. The technology is designed to restore IFN-β levels suppressed by viral pathogens and applies across multiple viruses including SARS-CoV-2, influenza, RSV, adenovirus, parainfluenza and rhinovirus, with delivery via a custom vibrating mesh nebuliser developed in partnership with Aerogen for use in mechanically-ventilated ICU patients. SNG001 has been evaluated across multiple Phase 1-3 programmes spanning asthma (SG004, SG005), COPD (SG015), hospitalised COVID-19 (SG016 Phase 2 in The Lancet Respiratory Medicine, SG018 SPRINTER Phase 3 in 17 countries), the NIH/NIAID-sponsored ACTIV-2 platform trial, the observational UNIVERSAL study with the University of Southampton and Janssen, and most recently the global Phase 2 INVENT study targeting 550 mechanically-ventilated patients with 28-day all-cause mortality as the primary endpoint.

The business model has historically been pre-revenue biotech development: funding has come from equity (notably a £18 million subscription from majority shareholder TFG Asset Management in January 2025) rather than product sales, and the intended future commercialisation pathway was a drug-device combination product (SNG001 + Aerogen nebuliser) sold to hospital systems, ICU networks and hospital pharmacies on a per-treatment pricing basis. Following the February 2026 termination of the INVENT trial due to under-recruitment and withdrawal of further financing from Tetragon Partners on behalf of TFG-managed funds, Synairgen is winding down operations and pursuing a Members Voluntary Liquidation in H2 2026, while conducting outreach to over 100 pharmaceutical and biotech companies to identify any potential acquirer for SNG001 intellectual property. The company has completed an all-staff redundancy, is closing its Southampton laboratory facility and US/EU subsidiaries, and was re-registered as a private limited company after AIM cancellation in April 2025.

Synairgen firmographics

Firmographics
Name
Synairgen
Legal name
Synairgen plc (UK operating entity); Synairgen Research Ltd (research subsidiary)
Website
https://synairgen.com
Company type
Private
Founded year
2003
Operating status
Closed
Headcount range
11–50 employees
Short description
Synairgen is a UK clinical-stage respiratory biotech developing SNG001, an inhaled interferon beta broad-spectrum antiviral for severe viral lung infections, delivered to mechanically-ventilated ICU patients via a custom Aerogen nebuliser. The company is winding down and pursuing Members Voluntary Liquidation in H2 2026.
Ownership category
akta.pro rank

Synairgen industry classification

Industry
Product category
Inhaled Antiviral Biologics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Respiratory biotechnology
  • Inhaled antivirals
  • Interferon beta therapy
  • Drug-device combination
  • Clinical-stage biopharmaceutical

Where Synairgen is headquartered

Location

Headquarters

HQ city
Southampton
HQ country
United Kingdom
HQ region
Europe

Offices6 records

Markets served

Synairgen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. No active revenue streams (winding down): Clinical-stage biotech with no approved or commercial products; company is winding down operations and pursuing Members Voluntary Liquidation in H2 2026. SNG001 has never been approved or available commercially. Intended future commercialisation via out-licensing or sale of SNG001 asset.
  2. Asset divestiture / IP licensing (exploratory): Company plans to explore whether there is any opportunity to divest certain intellectual property assets related to SNG001, with outreach to over 100 pharmaceutical and biotech companies to identify potential acquirers for the sole asset.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo product pricing available; investigational therapy not approved or commercially available anywhere.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels9 records

Synairgen product offering

Product offering

Core offering

Synairgen is a clinical-stage respiratory biotechnology company developing SNG001, an investigational inhaled formulation of interferon beta (IFN-β) delivered directly to the lungs as a host-directed broad-spectrum antiviral for severe viral lung infections. The company's programmes span asthma, COPD, COVID-19 and mechanically-ventilated ICU patients, with delivery via a custom nebuliser co-developed with Aerogen Ltd. Following termination of the Phase 2 INVENT trial in February 2026, Synairgen is winding down operations and seeking asset acquirers for SNG001.

Product overview

Synairgen plc is a UK-based clinical-stage respiratory biotechnology company whose sole clinical-stage asset is SNG001, an investigational inhaled formulation of interferon beta (IFN-β) being developed as a host-directed, broad-spectrum antiviral delivered directly into the lungs for severe viral lung infections. SNG001 has been evaluated across a portfolio of named clinical programmes spanning multiple patient populations: SG004 (Phase 1 in moderate asthma) and SG005 (Phase 2 in moderate-to-severe asthma), SG015 (Phase 2 in COPD), SG016 (Phase 2 in hospitalised COVID-19), SG018 SPRINTER (Phase 3 in hospitalised COVID-19 across 17 countries), the NIH/NIAID-sponsored ACTIV-2 trial, the observational UNIVERSAL study in collaboration with the University of Southampton and Janssen, and most recently the global Phase 2 INVENT study in mechanically-ventilated ICU patients, which dosed its first patient on 8 December 2025 before being terminated in February 2026 due to insufficient enrolment. Following the INVENT termination and the withdrawal of further financing from Tetragon Partners/TFG Asset Management UK LLP, Synairgen is winding down operations and pursuing a Members Voluntary Liquidation in H2 2026, while conducting outreach to potential acquirers for SNG001, which is delivered using a custom aerosol device developed in partnership with Aerogen Ltd.

Differentiator

Problem solved

Functional benefit

Brands

  • SNG001: Investigational inhaled formulation of interferon beta (IFN-β) developed by Synairgen as a broad-spectrum antiviral for severe viral lung infections.
  • Host Directed

Products and services

  • SNG001 (inhaled interferon beta) Investigational inhaled formulation of interferon beta (IFN-β), a naturally occurring broad-spectrum antiviral protein, designed to restore IFN-β levels in the lungs and boost antiviral responses in patients with severe viral lung infections (RSV, rhinovirus, influenza, SARS-CoV-2, MERS-CoV, etc.). Delivered via a nebuliser, including on invasive mechanical ventilation, through a custom device developed with Aerogen Ltd. Granted FDA Fast Track status; not approved anywhere in the world and is the sole asset of Synairgen.

Quantifiable outcome

  • Approximately 2 million people hospitalised in the US annually due to severe respiratory viral infections (HCUP).
  • +4 more outcomes

Companies that use Synairgen

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Synairgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Synairgen partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship / core, important, core, strategic (us government-sponsored) and standard adviser.

  • Aerogen Ltd.flagship / coreStrategic or Co-development Partner · 12 November 2025Strategic partnership announced 12 November 2025 to develop and deliver a custom aerosol device for SNG001 (inhaled interferon-beta). Builds on a long-standing relationship and unites Aerogen's vibrating mesh nebuliser platform and manufacturing expertise with Synairgen's drug development programme. Manufacturing, supply and exclusivity terms are in place for future commercialisation. Aerogen's Solo nebuliser is the gold standard for respiratory patient care in over 80 countries, treating over 30 million patients worldwide.
  • Asset MatchimportantChannel Partner/ Reseller/ Distributor · 8 May 2025Asset Match, an FCA-authorised firm (FRN 579310), operates an electronic off-market dealing facility for Synairgen ordinary shares following the company's cancellation from AIM trading in April 2025. Shares were admitted to trading on Asset Match on 8 May 2025 ahead of the first auction. Facility to remain in place for a minimum of two years from AIM cancellation (until 9 April 2027). Periodic auctions enable existing shareholders and new investors to trade shares.
  • University of Southampton (Clinical Trials Unit)coreImplementation/ SI/ Consulting Partner · 5 September 2022Long-standing research and academic collaboration. Synairgen was founded as a 2003 spin-out from the University of Southampton by three of its professors. Co-leads the UNIVERSAL observational trial. Prof Tom Wilkinson is a key opinion leader and Prof Ratko Djukanovic is a co-founder and Professor of Medicine.
  • U.S. National Institute of Allergy and Infectious Diseases (NIAID) / NIH ACTIV-2 Programmestrategic (us government-sponsored)Strategic or Co-development Partner · 1 October 2021SNG001 was investigated independently as part of the US National Institute of Health's ACTIV programme to accelerate the development of the most promising COVID-19 treatments. The ACTIV-2 study (ClinicalTrials.gov Identifier: NCT04518410) was sponsored by NIAID. An Independent Data Safety Monitoring Board recommended advancement from Phase 2 to Phase 3 in October 2021, but NIAID halted all patient recruitment in March 2022.
  • BDO LLPstandard adviserImplementation/ SI/ Consulting PartnerAuditors of Synairgen. Based at Level 12, Thames Tower, Station Road, Reading, RG1 1LX, UK. Reports to the Audit Committee chaired by independent Non-Executive Director John Bradshaw.
  • MUFG Corporate Marketsstandard adviserImplementation/ SI/ Consulting PartnerRegistrars for Synairgen, based at Central Square, 29 Wellington Street, Leeds, LS1 4DL. Issue share certificates on behalf of SNG to registered legal shareholders following AIM cancellation.
  • Fieldfisherstandard adviserImplementation/ SI/ Consulting PartnerSolicitors for Synairgen, based at Riverbank House, 2 Swan Lane, London, EC4R 3TT.
  • ICR Healthcarestandard adviserGTM or Marketing PartnerFinancial PR and Investor Relations adviser, based at 85 Gresham Street, London, EC2V 7NQ. Handles media and investor relations for Synairgen including distribution of corporate updates and clinical trial announcements.

Scale indicators13 records

Recent moves7 records

Expansion highlights3 records

Synairgen competitors and assessment

Company assessment

Direct peers

  • Ansun Biopharma: Clinical-stage developer of DAS181, an inhaled antiviral for severe respiratory infections including parainfluenza and influenza. Direct competitor to Synairgen's inhaled host-directed antiviral approach in the hospitalised/immunocompromised respiratory niche.
  • Pulmatrix: Clinical-stage biotech developing inhaled therapeutics for respiratory diseases using its iSPERSE/iCALM delivery platforms. Highly comparable as a small inhaled-respiratory biotech targeting severe pulmonary indications.
  • Soligenix: Late-stage biopharmaceutical company developing RiVax (ricin toxin) and other infectious disease/vaccine assets. Comparable small clinical-stage biotech operating in the antiviral/anti-infective space with similar capital constraints.

Broad incumbents

  • Shionogi: Japanese pharma with approved antivirals (baloxavir for influenza, Xocova/ensitrelvir for COVID-19). Competes with SNG001 in the respiratory antiviral space via direct-acting mechanisms with much larger commercial infrastructure.
  • Alnylam Pharmaceuticals: Leading RNAi therapeutics company with programmes in infectious disease (incl. respiratory targets). Larger incumbent with broader modality portfolio and stronger balance sheet but overlapping antiviral development programmes.
  • Pfizer: Develops and commercialises Paxlovid (nirmatrelvir/ritonavir) for COVID-19 and other respiratory antivirals. The most likely strategic acquirer profile for SNG001 given its hospital antiviral portfolio and ICU commercial reach.
  • Translate Bio (Sanofi): Sanofi-owned mRNA therapeutics platform that was developing vaccines for respiratory viruses including influenza. Represents the broader incumbent respiratory antiviral space and a potential acquirer/category competitor for SNG001.

Emerging players

  • Arcturus Therapeutics: Develops mRNA-based vaccines and therapeutics for infectious disease including respiratory viruses (e.g., Kostaive for COVID-19). Comparable clinical-stage respiratory biotech targeting viral lung infections through a different modality.
  • Vaxart: Clinical-stage developer of oral vaccines for respiratory viruses including RSV and influenza. Comparable small-cap respiratory infectious disease biotech with similar wind-down/trial-recruitment sensitivities.
  • Aiolos Bio: Clinical-stage respiratory biotech (acquired by GSK in 2024) developing inhaled therapeutics for severe asthma and COPD exacerbations. Closely comparable single-asset inhaled respiratory biotech whose acquisition illustrates the exit path Synairgen is pursuing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Synairgen social profiles

Digital presence

Synairgen compliance and trust

Trust signal

Compliance2 records

Synairgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synairgen leadership team

Management profile

Number of profiles

Profiles10 records

Synairgen subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Synairgen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synairgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synairgen

What does Synairgen do?

Synairgen is a clinical-stage respiratory biotechnology company developing SNG001, an investigational inhaled formulation of interferon beta (IFN-β) delivered directly to the lungs as a host-directed broad-spectrum antiviral for severe viral lung infections. The company's programmes span asthma, COPD, COVID-19 and mechanically-ventilated ICU patients, with delivery via a custom nebuliser co-developed with Aerogen Ltd. Following termination of the Phase 2 INVENT trial in February 2026, Synairgen is winding down operations and seeking asset acquirers for SNG001.

Is Synairgen a public or private company?

Synairgen is a private company. It is classified as venture growth investor backed and is currently closed.

When was Synairgen founded?

Synairgen was founded in 2003. It employs 11 to 50 people.

Where is Synairgen based?

Synairgen is headquartered in Southampton, United Kingdom, in the Europe region.

How does Synairgen make money?

Two revenue lines are on record. No active revenue streams (winding down) is the primary driver. The others are asset divestiture / IP licensing (exploratory).

Who are Synairgen's main competitors?

Direct peers on record are Ansun Biopharma, Pulmatrix and Soligenix. Broad incumbents are Shionogi, Alnylam Pharmaceuticals, Pfizer and Translate Bio (Sanofi). Emerging players are Arcturus Therapeutics, Vaxart and Aiolos Bio.

Does Synairgen have an API?

No public API is recorded for Synairgen.

What industry is Synairgen in?

Synairgen's product category is Inhaled Antiviral Biologics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAJ, RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyApollo vaccine triggers broad rhinovirus immunity in Phase 1Apollo Therapeutics reported Phase 1 data showing its rhinovirus vaccine APL-10456 induced immune responses against all three rhinovirus species in healthy adults. The trial enrolled 144 volunteers, with no serious adverse events, and results from the older-age cohort are expected in Q4 2026. Apollo plans a Phase 2 trial in COPD patients in 2027.Investing.comSynairgen provides liquidation timeline, expects £5m distribution By Investing.comSynairgen Limited, a clinical-stage biotechnology company based in Southampton, has provided a timeline for its Members' Voluntary Liquidation process, with wind-down activities progressing as expected including closure of its Phase 2 INVENT clinical study and company operations. The company expects to distribute over £5 million to shareholders across two tranches, with the first interim distribution scheduled for October 2026 and a final distribution in the first half of 2027, pending shareholder approvals at a general meeting in September.Investing.comSynairgen progresses wind-down, targets liquidation this year By Investing.comSynairgen Limited, a clinical-stage biotechnology company, is proceeding with plans to wind down operations and pursue Members Voluntary Liquidation in H2 2026 after terminating its phase 2 INVENT clinical study for SNG001 (inhaled interferon beta). The company is closing its laboratory facility at Southampton General Hospital, CMC activities, and subsidiaries in the US and EU, having completed a staff redundancy process, and has initiated outreach to over 100 pharmaceutical and biotech companies to identify potential acquirers for its sole asset. Directors expect to complete initial wind-down steps and make an initial distribution to shareholders in H2 2026.Investing.comSynairgen progresses wind-down, targets liquidation this year By Investing.comSynairgen Limited is proceeding with plans to wind down operations and pursue a Members Voluntary Liquidation in the second half of 2026, after terminating its phase 2 INVENT clinical study for SNG001 (inhaled interferon beta) earlier this year. The board determined in February that returning available cash to shareholders was in the best interests of stakeholders after reviewing alternative study designs and strategic options, with the company now closing its Southampton laboratory facility and US/EU subsidiaries. The company has initiated outreach to over 100 pharmaceutical and biotechnology companies to identify potential acquirers for SNG001, with directors engaging an Insolvency Practitioner ahead of the formal MVL process and expected initial shareholder distribution in H2 2026.Investing.comSynairgen to wind down operations after halting trial By Investing.comSynairgen Limited announced it will terminate its phase 2 INVENT clinical trial of SNG001, an inhaled interferon beta treatment for mechanically-ventilated patients with respiratory viruses, and begin winding down operations. The company cited significantly below-expectation trial enrollment due to an unusually mild winter viral season, and after reviewing alternative study designs with external experts, concluded no viable path forward existed without substantial additional funding. Tetragon Partners, the majority shareholder, confirmed it would not provide further financing, leading the board to determine an orderly wind-down is in shareholders' best interests.Investing.comFirst patient dosed in Synairgen’s global phase 2 INVENT study By Investing.comSynairgen announced that the first participant has been dosed in its global Phase 2 INVENT clinical study evaluating SNG001, an inhaled interferon-beta treatment for mechanically-ventilated patients with respiratory viral infections. The randomized, placebo-controlled, double-blind trial aims to enroll 550 patients across ICU sites in the US, UK, and selected European countries, with 28-day all-cause mortality as the primary endpoint. A protocol-defined interim analysis is scheduled during 2026.FieldfisherFieldfisher advises on Synairgen's £18 million fundraisingSynairgen raised £18 million from TFG Asset Management UK, its major shareholder, with a rule 9 waiver. The funds will support a Phase II trial of SNG001 in mechanically ventilated patients with respiratory viral infections, with plans to start the trial in coming months.European BiotechnologySynairgen raises £18m for Phase 2 INVENT trial of SNG001Synairgen raised £18m from TFG Asset Management for its Phase 2 INVENT trial of SNG001 in mechanically ventilated patients. The trial will test whether the drug reduces mortality, with proceeds covering costs up to interim analysis. New shares will be issued pending shareholder approval on 16 January 2025.Synairgen£18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infectionsSynairgen raised £18 million through a subscription from TFG Asset Management to fund Phase 2 INVENT trial of SNG001, a broad-spectrum antiviral, in ventilated patients with severe viral lung infections. The funds will cover trial costs, drug manufacturing, and stability testing, with plans to start the trial in the coming months. The company intends to seek shareholder approval to proceed with the share issue, which may result in the cancellation of its AIM listing.MarketScreenerSynairgen narrows interim loss on reduced R&D spendingSynairgen's interim loss narrowed to GBP5.2 million in six months ending June 30, down from GBP14.0 million a year earlier, with no revenue either year. R&D spending fell to GBP3.5 million from GBP11.1 million as the phase 3 Sprinter trial of SNG001 is mostly completed in 2022.